Ferrante R J, Spillert C R, Wilson D J, Lazaro E J
Department of Surgery, UMDNJ-New Jersey Medical School, Newark 07103.
Agents Actions. 1993;39 Spec No:C102-3. doi: 10.1007/BF01972734.
Thromboembolic complications have been described in graft recipients receiving cyclosporine (CS). Whether these individuals have a hypercoagulable state when compared to healthy controls was evaluated. Recalcification times (RT) of saline-incubated citrated whole blood and endotoxin-incubated whole blood of both control and transplant patients were determined. There was no difference between the RT saline or RT endotoxin groups in both patient groups. These data suggest that CS alone has no procoagulant effects, but that additional factors such as endotoxin and/or graft-induced antigen production may provoke the thrombotic complications.
在接受环孢素(CS)治疗的移植受者中已描述有血栓栓塞并发症。本研究评估了与健康对照相比,这些个体是否处于高凝状态。测定了对照组和移植患者的枸橼酸化全血在生理盐水孵育及内毒素孵育后的再钙化时间(RT)。两个患者组的生理盐水孵育RT组和内毒素孵育RT组之间均无差异。这些数据表明,单独使用CS没有促凝作用,但内毒素和/或移植诱导的抗原产生等其他因素可能引发血栓形成并发症。